Oncoinvent Hits Halfway Mark in Phase II Ovarian Cancer Trial, Preps for Pivotal Phase III

Phase II Momentum

Oncoinvent's first half of 2026 has delivered on its core promise: speeding up recruitment in the pivotal Phase II trial of Radspherin in ovarian cancer. As CEO Oystein Soug highlighted, "the most important value driver in the company for us today is the execution of the Phase II trial in ovarian cancer. And we included 4 additional sites into that trial during the 2 first quarters. So now we have 55 patients recruited into that trial." This marks the fastest recruitment quarters since the trial began randomizing in Q1 2025, crossing the halfway mark with 10 active sites across Europe. The company also made small protocol amendments—such as allowing local HRD testing and broadening chemotherapy cycles—that iron out operational wrinkles without compromising patient homogeneity.

This progress is not just operational; it feeds directly into the data pipeline. The company presented Phase I data at ESGO, published dosimetry results in the Journal of Nuclear Medicine, and has abstracts accepted at ESMO and EANM. As Soug noted, the upcoming interim analysis will be a key inflection: "we announced that we will have the most important interim readout at the end of 2027 or the second half of 2027, which is after 9 months follow-up." With the current recruitment rate, the company implicitly guides that the last patient will be enrolled by early 2027, setting the stage for a readout that could trigger regulatory discussions.

Preparing for Phase III

Even before the Phase II data matures, Oncoinvent is actively preparing for the next stage. CFO Ramzi Amri detailed a multipronged strategy in the Q&A:

For Phase III, we need redundancy. And we need a partner outside of Europe for logistical reasons and for the volume of the trial. That partner is also going to be a candidate for commercial manufacturing.

The Fast Track designation with the FDA adds optionality for accelerated approval, though Amri was measured: "Never say never... Fast Track can absolutely help because it gives us the opportunity, of course, to have an open dialogue about accelerated approval in the subpopulation based on an interim of the Phase III." Still, the formal stance remains that a randomized Phase III will be required before approval, given the need to build a robust safety database.

Financial Discipline

On the balance sheet, Oncoinvent's cash runway remains solid. As of June 30, cash and equivalents totaled NOK 109 million plus NOK 2 million restricted, which management expects to fund operations into 2027 "beyond the interim." The operating cash burn was NOK 69 million in H1, in line with budget, despite the surge in recruitment activity. CFO Amri emphasized the efficiency: "we managed to keep the costs very much in control... our operating expenses are very stable despite a significant increase in the number of patients we are recruiting." This discipline is crucial for a small biotech with a single shot on goal and no revenue.

The company is also actively pursuing partnerships, though details remain confidential. As Amri put it, "we have strategic discussions, BD discussions, discussions with investors at any point in time through the year." The market should watch for announcements around the ESMO/EANM presentations later this year, where data will be shared.

What Changed and Why It Matters

The narrative has shifted from early-stage promise to execution mode. Oncoinvent is no longer just talking about a novel alpha emitter; it is delivering on recruitment, preparing manufacturing for scale, and laying the groundwork for a pivotal trial. The interim data due later this year will be the first real test of whether the Phase II confirms the compelling Phase I signal (only 1 of 10 patients recurring at 2 years). If successful, the company could enter Phase III by 2027 with a head start—both in site activation and regulatory alignment.

For investors, the key risks are execution and dilution. The company's cash position is tight, and a Phase III study of multiple hundred patients will require substantial funding, likely through a partner or equity raise. However, the recent appointment of a new CFO and the explicit focus on cost control suggest a disciplined path forward. The share price history is short—a reminder that Oncoinvent only started its current incarnation after a reverse merger in late 2025—so any misstep could amplify volatility.